The 10-second takeaway
For the quarter ended March 31 (Q1), Pacira Pharmaceuticals whiffed on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP loss per share increased.
Margins dropped across the board.
Pacira Pharmaceuticals recorded revenue of $11.6 million. The four analysts polled by S&P Capital IQ wanted to see net sales of $13.2 million on the same basis. GAAP reported sales were 48% higher than the prior-year quarter's $7.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.71. The five earnings estimates compiled by S&P Capital IQ predicted -$0.42 per share. GAAP EPS were -$0.71 for Q1 compared to -$0.47 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 1.7%, much worse than the prior-year quarter. Operating margin was -160.9%, much worse than the prior-year quarter. Net margin was -199.7%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $16.6 million. On the bottom line, the average EPS estimate is -$0.33.
Next year's average estimate for revenue is $74.6 million. The average EPS estimate is -$1.22.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 22 members out of 33 rating the stock outperform, and 11 members rating it underperform. Among seven CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give Pacira Pharmaceuticals a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $31.60.
- Add Pacira Pharmaceuticals to My Watchlist.